spacer
home > ebr > winter 2019 > channelling the future of liposome generation
PUBLICATIONS
European Biopharmaceutical Review

Channelling the Future of Liposome Generation

The pharmaceutical industry has increasingly adopted liposomes as a means of drug delivery thanks to their biocompatibility and suitability for both hydrophilic and hydrophobic substrates. A number of factors, such as average diameter, size distribution, and lamellarity (number of bilayers), play a crucial role in determining the drug release profile, and existing batch production methods do not offer the level of control needed for fine-tuning of parameters. More recently, microfluidics has established itself as a desirable alternative, offering consistent particle diameters, narrow size distribution, and good batch-to-batch reproducibility.

Encapsulating a drug in a nano- or microparticle is an increasingly popular method for drug delivery. For starters, encapsulation protects an enclosed molecule from enzymatic or acidic degradation in the stomach, improves diffusion of the drug across the digestive tract, and provides a means by which hydrophobic molecules can be introduced into the body. Additionally, it enables the administration of a number of potential drugs, which often cannot be routinely used due to their toxicity and associated side effects. Despite their excellent antimicrobial properties, these drugs frequently display poor pharmacokinetics and pharmacodynamics – drawbacks that can be offset through encapsulation. Formulating these nanoor microparticles to extend their circulating half-life can help maintain higher therapeutic levels of the drug, reducing the number of doses a patient receives. A final consideration is the ability to modify the particle to encourage adsorption by specific cells. Binding proteins or antibodies to the external surface or adjusting the drug release profile to respond to a particular temperature or pH are all ways of introducing selective targeting, a powerful feature of drug delivery via encapsulation.

An Ideal Candidate

The liposome is one particular microparticle formulation that has attracted a lot of attention. Liposomes are vesicular nano- or microparticles consisting of one or more lipid bilayers encapsulating an internal aqueous core. The bilayers are made of amphiphilic phospholipids – two hydrophobic fatty acid ‘tails’ and a hydrophilic phosphate ‘head’ – which aggregate and self-assemble, exposing the phosphate groups to the aqueous environment and turning the fatty acid tails inwards. Cholesterol is often an additional component in the liposome membrane, thanks to the benefits it brings. It increases the thermal stability of the liposome, as well as reducing the membrane permeability, therefore aiding encapsulation and retention of the drug until it is ready to be released.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After completing his Master’s degree in chemical engineering, Damiano Rossi joined the University of Pisa, Italy, as a material scientist working on the formulation of new energetic copolymer binders and adhesive membranes. He obtained a PhD in chemical engineering from University College London, UK, where he worked on the development of microfluidic devices for continuous sonocrystallisation of APIs. Today, Damiano is a technical applications specialist at Blacktrace, where he is responsible for overseeing applications relating to particle engineering and Dolomite Microfluidics’ products.

After completing a Bachelor’s degree in chemical and biological engineering, Anna Blakney pursued a PhD in bioengineering at the University of Washington, US, with a focus on the development of electrospun fibers for multipurpose prevention of pregnancy and HIV. She is now a postdoctoral research fellow at Imperial College London, UK. Anna’s current research is on the formulation of self-amplifying RNA vaccines, including nanoparticle systems, such as liposomes and polyplexes, for optimal cellular uptake, expression, and immunogenicity.
spacer
Damiano Rossi
spacer
spacer
spacer
Anna Blakney
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Appointment of Lisa Spence as Director of Clinical Supply Chain International Region

Philadelphia, PA – March 12, 2019. Leading biopharmaceutical services provider PCI Clinical Services (PCI) is pleased to announce the appointment of Lisa Spence as Director of Clinical Supply Chain – International Region.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement